InstalabLoading...
InstalabLoading...
If you have ever wondered whether your body is producing adequate growth signals, IGF-1 (insulin-like growth factor 1) offers a window into that question. This hormone reflects how much growth hormone your pituitary gland is releasing over the course of a day, and it influences everything from muscle mass and bone density to how your cells grow, repair, and age. Unlike growth hormone itself, which surges and dips throughout the day, IGF-1 circulates at relatively stable levels, making it far easier to measure with a single blood draw.
What makes IGF-1 especially interesting from a health perspective is its dual nature. During youth, robust IGF-1 signaling fuels growth and protects against disease. But as you age, the relationship becomes more complicated. Both very high and very low levels are associated with increased mortality, forming a U-shaped curve. This means the goal is not simply "more is better" or "less is better" but rather finding a middle range where your body's growth signaling is balanced.
IGF-1 testing has well-established clinical uses: screening for growth hormone excess (a condition called acromegaly), evaluating growth disorders in children, and assessing growth hormone deficiency in adults.
Your pituitary gland releases growth hormone in pulses throughout the day, especially during sleep and exercise. Growth hormone then travels to the liver, where it activates a signaling pathway that triggers IGF-1 production. Because IGF-1 levels reflect the sum of all those growth hormone pulses, a single IGF-1 measurement gives you a reliable snapshot of your average growth hormone output, something that would otherwise require repeated blood draws over many hours.
Once released, about 98% of IGF-1 in your blood is bound to carrier proteins, mainly one called IGFBP-3. This binding extends IGF-1's active life in the bloodstream to roughly 15 hours, compared to just 20 to 30 minutes for growth hormone itself. The carrier proteins also control how much IGF-1 actually reaches your tissues.
There is one important nuance: IGF-1 production depends not only on growth hormone but also on insulin delivered directly from the pancreas to the liver through a dedicated blood vessel. When this insulin supply changes, as it does in poorly controlled diabetes or liver disease, IGF-1 levels can become disconnected from what growth hormone is actually doing. This means your IGF-1 result can sometimes be misleading if you have underlying metabolic or liver conditions.
Beyond its role as a circulating hormone, IGF-1 is also produced locally within tissues, including muscle, bone, and brain. This locally produced IGF-1 acts on nearby cells without entering the general bloodstream, supporting tissue-specific functions like muscle repair, bone maintenance, and the formation of new brain connections. A standard blood test captures only the circulating form, not these important local signals.
One of the most striking findings about IGF-1 is that its relationship to lifespan follows a U-shaped curve. A meta-analysis of nearly 31,000 people found that compared to those with mid-range IGF-1 levels, people with low IGF-1 had about a 33% higher risk of dying from any cause, while those with high IGF-1 had about a 23% higher risk. The range associated with the lowest mortality was approximately 120 to 160 ng/mL.
This pattern reflects a concept called antagonistic pleiotropy, which means a trait that helps you early in life can hurt you later. A study of over 440,000 people in the UK Biobank found that younger individuals with higher IGF-1 were actually protected against disease and death, while older individuals with similarly high levels faced increased risk. In practical terms, the growth signaling that builds your body during youth may accelerate wear and aging later on.
Interestingly, the stability of your IGF-1 levels over time may matter as much as the absolute number. In the Cardiovascular Health Study, older adults whose IGF-1 remained steady had lower mortality than those whose levels fluctuated, regardless of whether those levels were high or low. A single measurement is still useful, but tracking your levels over time adds another dimension to the picture.
| Who Was Studied | What Was Compared | What They Found |
|---|---|---|
| About 31,000 adults across multiple studies | Low, middle, and high IGF-1 levels and risk of death from any cause | Low IGF-1 was linked to roughly 33% higher mortality risk; high IGF-1 to about 23% higher risk, compared to mid-range levels (120 to 160 ng/mL) |
| Over 440,000 UK Biobank participants across age groups | High vs. low IGF-1 and risk of disease and death by age | High IGF-1 was protective in younger adults but harmful in older adults |
| Older adults in the Cardiovascular Health Study, tracked over time | Stable vs. fluctuating IGF-1 trajectories and mortality | Stable IGF-1 levels over time were associated with lower mortality, regardless of the actual concentration |
Sources: Rahmani et al. meta-analysis; Zhang et al. (UK Biobank); Sanders et al. (Cardiovascular Health Study).
What this means for you: if your IGF-1 falls in the mid-range and stays relatively stable over repeated tests, that is a reassuring signal. If it is very high or very low, it is worth investigating the cause rather than assuming one direction is inherently better.
IGF-1 levels vary substantially by age and sex, peaking during puberty and declining steadily through adulthood. Any meaningful interpretation of your result requires comparison to age-specific and sex-specific reference ranges. A level that is perfectly normal for a 25-year-old could be unusually high for a 65-year-old. Different laboratory assays can also produce significantly different numbers, even when using the same calibration standards, so comparing results between labs requires caution.
Several factors can push your IGF-1 lower than your true growth hormone status would predict. These include:
Conversely, pregnancy and late adolescence can produce elevated levels that do not indicate disease. When your result sits at one extreme or the other, consider whether any of these common confounders could be contributing before pursuing further workup.
For clinical purposes, IGF-1 is most useful in two specific diagnostic roles. As a screening test for acromegaly (a condition of growth hormone excess, usually caused by a pituitary tumor), it has 90 to 95% sensitivity and specificity when age-adjusted reference ranges are used. For growth hormone deficiency in adults, it is less sensitive: only about 41% of adults with confirmed growth hormone deficiency have IGF-1 levels below the expected range. This means a normal IGF-1 does not rule out growth hormone deficiency, but a very low result is a strong signal worth investigating.
Because IGF-1 is primarily driven by growth hormone and insulin, interventions that influence either of those hormones will affect your levels. However, the relationship between lifestyle factors and circulating IGF-1 is more nuanced than many popular health sources suggest.
Exercise stimulates growth hormone release and increases local IGF-1 production within muscle tissue. However, circulating IGF-1 levels do not reliably change with exercise training. Longitudinal studies show that people can gain significant muscle strength, improve performance, and increase cardiovascular fitness without any corresponding rise in blood IGF-1 levels. This is because the exercise benefits on muscle appear to be driven primarily by IGF-1 produced locally within the muscle, not the circulating form that a blood test measures.
Nutrition has a meaningful influence. Adequate caloric and protein intake supports hepatic IGF-1 production, while malnutrition or severe caloric restriction suppresses it. The relationship between diet composition and IGF-1 is an area of active investigation, particularly given the observation from animal studies that reduced IGF-1 signaling extends lifespan.
Growth hormone therapy directly raises IGF-1 and is an established treatment for confirmed growth hormone deficiency. However, the Growth Hormone Research Society has explicitly stated that growth hormone use in healthy older adults for anti-aging purposes cannot be recommended. The marginal benefits observed in studies of healthy aging adults are counterbalanced by concerning side effects. In animal models, reducing growth hormone and IGF-1 signaling actually extends lifespan and protects against cancer and diabetes, and in humans, certain genetic conditions that reduce growth hormone signaling appear to offer similar protection, though effects on overall longevity are inconsistent.
Given the U-shaped mortality curve and the lack of validated interventions for optimizing IGF-1 in healthy adults, the most reasonable approach is to ensure adequate nutrition, stay physically active, and address any underlying conditions that could be artificially suppressing or elevating your levels.